CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 37 enrolled
Drug / intervention
nintedanib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02606877
NCT02606877Phase 4Completed

Investigation of Drug-drug Interaction Between Nintedanib and Pirfenidone in Patients With IPF (an Open Label, Multiple-dose, Two Group Study)

Boehringer Ingelheim·interventional·Posted Nov 17, 2015·Updated Mar 4, 2019

In Brief

A Phase 4 clinical trial evaluating nintedanib and pirfenidone for Idiopathic Pulmonary Fibrosis. Completed, enrolled 37 participants across 9 sites.

Detailed Summary

The primary objective of this study is to investigate the effect of steady state pirfenidone on the pharmacokinetics of nintedanib and its metabolites following oral administration of 2403 mg/day pirfenidone and to investigate the effect of steady state nintedanib on the pharmacokinetics of pirfenidone at steady state following oral administration of 150 mg bid nintedanib. There will be two cohorts of patients; the first one will consist of patients not treated with pirfenidone or nintedanib, while the second one will consist of patients on pirfenidone treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 17, 2015
Enrollment StartApr 19, 2016
Primary CompletionMar 22, 2017
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 10.6 years ago

Interventions

nintedanibdrug

pirfenidonedrug